Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System

[In The News]

TOKYO and CAMBRIDGE, England, Dec. 21, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with GlaxoSmithKline ("GSK")[1]. The single-target agreement is focused on the discovery and...

View the full article